Cue Biopharma (CUE) Profit After Tax (2017 - 2025)

Cue Biopharma has disclosed Profit After Tax across 9 years of filings, most recently posting $1.6 million for Q4 2025.

• Profit After Tax for Q4 2025 came in at $1.6 million, up 116.69% year-over-year; the trailing twelve-month figure through Dec 2025 was -$26.6 million (up 34.6% YoY), and the FY2025 annual result was -$26.6 million, up 34.6% from the prior year.
• Profit After Tax came in at $1.6 million for Q4 2025 at Cue Biopharma, up from -$7.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $1.6 million in Q4 2025 to a low of -$14.6 million in Q4 2022.
• The 5-year median for Profit After Tax is -$11.6 million (2023), against an average of -$10.8 million.
• Across the five-year window, Profit After Tax sank 74.04% in 2022 and surged 116.69% in 2025, its largest moves.
• Cue Biopharma's Profit After Tax stood at -$8.4 million in 2021, then tumbled by 74.04% to -$14.6 million in 2022, then advanced by 7.94% to -$13.4 million in 2023, then advanced by 29.31% to -$9.5 million in 2024, then jumped by 116.69% to $1.6 million in 2025.
• The last three Profit After Tax figures came in at $1.6 million (Q4 2025), -$7.4 million (Q3 2025), and -$8.5 million (Q2 2025), per Business Quant data.